Artigo Acesso aberto Revisado por pares

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

2018; American Association for the Advancement of Science; Volume: 10; Issue: 436 Linguagem: Inglês

10.1126/scitranslmed.aao5931

ISSN

1946-6242

Autores

János L. Tanyi, Sara Bobisse, Eran Ophir, Sandra Tuyaerts, Annalisa Roberti, Raphaël Genolet, Petra Baumgärtner, Brian J. Stevenson, Christian Iseli, Denarda Dangaj, Brian J. Czerniecki, Aikaterini Semilietof, Julien Racle, Alexandra Michel, Ioannis Xénarios, Cheryl Lai-Lai Chiang, Dimitri Monos, Drew A. Torigian, Harvey Nisenbaum, Olivier Michielin, Carl H. June, Bruce L. Levine, Daniel J. Powell, David Gfeller, Rosemarie Mick, Urania Dafni, Vincent Zoete, Alexandre Harari, George Coukos, Lana E. Kandalaft,

Tópico(s)

Immune Cell Function and Interaction

Resumo

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC was administered alone (cohort 1, n = 5), in combination with bevacizumab (cohort 2, n = 10), or bevacizumab plus low-dose intravenous cyclophosphamide (cohort 3, n = 10) until disease progression or vaccine exhaustion. A total of 392 vaccine doses were administered without serious adverse events. Vaccination induced T cell responses to autologous tumor antigen, which were associated with significantly prolonged survival. Vaccination also amplified T cell responses against mutated neoepitopes derived from nonsynonymous somatic tumor mutations, and this included priming of T cells against previously unrecognized neoepitopes, as well as novel T cell clones of markedly higher avidity against previously recognized neoepitopes. We conclude that the use of oxidized whole-tumor lysate DC vaccine is safe and effective in eliciting a broad antitumor immunity, including private neoantigens, and warrants further clinical testing.

Referência(s)